Stockscreener 앱 받기
79.31
0.81%
-0.65
시장 영업 전:
79.44
0.13
+0.16%
Merck Co Inc 주식(MRK)의 최신 뉴스
Lobbying Update: $4,980,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative
Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production - Insider Monkey
Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - The Motley Fool
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest
Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey
Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating - Insider Monkey
Merck KGaA gets EU nod for Ezmekly (MRK:NYSE) - Seeking Alpha
Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions - Yahoo Finance
Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - Insider Monkey
Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges - Investing.com
Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges By Investing.com - Investing.com UK
Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha
Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer - MSN
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention - Yahoo Finance
The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team - Yahoo Finance
Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally - MarketScreener
Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention - MarketScreener
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill - Business Wire
Verona Pharma (VRNA) Opinions on Merck Acquisition News - Quiver Quantitative
Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer - MSN
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects - MSN
Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more - Seeking Alpha
Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition - Yahoo Finance
Success Tricking FDA Shouldn't Protect Merck, Justices Told - Law360
Merck to Acquire Verona Pharma in $10B Bid - USA Herald
Top Analyst Reports for Microsoft, Alibaba & Merck - TradingView
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Yahoo Finance
With Verona deal, Merck wagers on strength of lung drug’s patents - BioPharma Dive
Merck: Jefferies raises TP after Verona acquisition - MarketScreener
Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating - MarketScreener
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? - Nasdaq
Merck Animal Health gets FDA nod for Bravecto Quantum (MRK:NYSE) - Seeking Alpha
Merck Animal Health's Flea-and-Tick Treatment Approved in U.S. - MarketScreener
QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Business Wire
Merck & Co. Remains In The BD Game After Verona Takeout - insights.citeline.com
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration - Insider Monkey
Merck's doravirine/islatravir under FDA review for HIV (MRK:NYSE) - Seeking Alpha
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
Merck to acquire UK drugmaker Verona Pharma for $10bn - World Pharmaceutical Frontiers
Foley Represents Verona Pharma in $10B Acquisition by Merck - Foley & Lardner LLP
Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance
Merck & Co.’s Verona Acquisition Marks A Return To Respiratory - insights.citeline.com
In a $10B deal, Merck buys cardio developer Verona - BioWorld MedTech
Merck spends $10 billion for Verona, gaining access to its COPD medication - Jacksonville Journal-Courier
Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue (NYSE:MRK) - Seeking Alpha
Merck to buy Verona and its lung drug in $10B deal - BioPharma Dive
Merck to Buy Verona Pharma in $10 Billion Deal - The Wall Street Journal
Merck to acquire Verona Pharma for $10 billion - Reuters
Verona Pharma Stock Jumps 20%. It’s Being Bought for $10 Billion by Merck. - Barron's
Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B - Investopedia
Freshfields Guides Merck's $10B Deal For Verona Pharma - Law360
Merck to Buy Verona for $10 Billion as Patent Cliff Looms - Bloomberg.com
Merck Faces Multiple Challenges: Will It Steer Through Successfully? - Yahoo Finance
Merck Makes Big Respiratory Play With $10B Acquisition of Verona - BioSpace
Transcript : Merck & Co., Inc., Verona Pharma plcM&A Call - MarketScreener
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq
0.95%
0.10%
자본화:
|
볼륨(24시간):